Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTCXNYSE:GBSNYSE:NSPRNASDAQ:TMDIF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTCXCarmell$2.44+0.8%$2.09$0.17▼$1.98$51.01M0.514.32 million shs10,621 shsGBSGBS$1.78-2.7%$1.52$0.36▼$2.89$26.50M1.32955,325 shs508,618 shsNSPRInspireMD$2.22-0.9%$2.43$1.99▼$3.80$68.01M0.5767,358 shs212,000 shsTMDIFTitan Medical$0.28-1.7%$0.28$0.03▼$1.00$31.93M1.2674,785 shs6,027 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTCXCarmell0.00%-5.79%-17.01%+1,973.07%+46.11%GBSGBS0.00%+16.34%+11.25%+31.85%-2.73%NSPRInspireMD0.00%-1.53%-9.80%-12.93%-5.65%TMDIFTitan Medical0.00%-2.10%0.00%-23.54%+600.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/AGBSGBSN/AN/AN/AN/AN/AN/AN/AN/ANSPRInspireMD3.383 of 5 stars3.54.00.00.02.72.50.6TMDIFTitan MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTCXCarmell 0.00N/AN/AN/AGBSGBS 0.00N/AN/AN/ANSPRInspireMD 3.00Buy$4.50102.70% UpsideTMDIFTitan Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GBS, NSPR, CTCX, and TMDIF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTCXCarmell$32.84K1,553.28N/AN/A$1.07 per share2.28GBSGBSN/AN/AN/AN/A$0.44 per shareN/ANSPRInspireMD$7.03M9.68N/AN/A$1.83 per share1.21TMDIFTitan Medical$17.63M1.81$14.00 per share0.02$1.05 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/AGBSGBS-$8.31M-$0.56N/AN/AN/AN/A-85.64%-54.42%N/ANSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ATMDIFTitan Medical$6.95M$0.05N/A∞N/AN/A-82.31%-51.47%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTCXCarmellN/AN/AN/AN/AN/AGBSGBSN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ATMDIFTitan MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTCXCarmellN/A0.310.29GBSGBSN/A2.332.33NSPRInspireMDN/A6.396.05TMDIFTitan MedicalN/A3.733.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTCXCarmell24.22%GBSGBS2.79%NSPRInspireMD44.78%TMDIFTitan Medical0.03%Insider OwnershipCompanyInsider OwnershipCTCXCarmell29.00%GBSGBS0.27%NSPRInspireMD34.06%TMDIFTitan Medical0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTCXCarmell1420.91 million14.84 millionNot OptionableGBSGBS714.89 million14.85 millionNot OptionableNSPRInspireMD5030.64 million18.33 millionOptionableTMDIFTitan Medical50114.04 million4.56 millionNot OptionableGBS, NSPR, CTCX, and TMDIF HeadlinesRecent News About These CompaniesTitan Medical Group Launches Titan Workforce Solutions: Launches to Transform Healthcare StaffingApril 29, 2025 | businesswire.comTitan Nurse Staffing, LLC and Titan Medical Group, LLC Announce Merger to Streamline Healthcare Staffing ServicesApril 29, 2025 | businesswire.comTitan MRI acquires High Field MRI, expanding Titan MRI's service to North Central FloridaDecember 3, 2024 | msn.comAttack on Titan movie release date, trailer, changes, and everything else we know about The Last AttackNovember 6, 2024 | gamesradar.comGConavi Medical Corp. (formerly “Titan Medical Inc.”) Completes Business CombinationOctober 11, 2024 | globenewswire.comTitan Announces the Closing of Conavi's Private Placement of Subscription Receipts and Provides Update on the TransactionOctober 8, 2024 | globenewswire.comTitan Announces Resignations of DirectorsOctober 2, 2024 | globenewswire.comTitan Reports Voting Results from 2023 Annual General and Special MeetingSeptember 30, 2024 | globenewswire.comTitan Medical begins process to move to the TSX Venture ExchangeSeptember 30, 2024 | globenewswire.comConavi Medical Shareholders Approve the Proposed Amalgamation Between Titan and ConaviSeptember 26, 2024 | globenewswire.comProxy Deadline Thursday September 26, 2024September 25, 2024 | globenewswire.comProxy Advisor Glass, Lewis & Co., Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 19, 2024 | globenewswire.comA key employee says the Titan sub tragedy could have been preventedSeptember 18, 2024 | postregister.comPTitan Announces Conavi Medical to Present Overview at Titan Q&A SessionSeptember 16, 2024 | globenewswire.comIndependent Proxy Advisor, Institutional Shareholder Services (“ISS”), Recommends Titan Shareholders Vote FOR the Amalgamation Between Titan and ConaviSeptember 16, 2024 | globenewswire.comTitan Announces Q&A Session with ShareholdersSeptember 9, 2024 | globenewswire.comTitan Announces Filing of the Management Information Circular.September 6, 2024 | globenewswire.comTitan Medical | Morning BlendSeptember 3, 2024 | msn.comTitan Medical Inc. (QTNA.SG)August 24, 2024 | finance.yahoo.comTitan Medical Reports Operating and Financial Results for the Second Quarter 2024August 15, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGBS, NSPR, CTCX, and TMDIF Company DescriptionsCarmell NASDAQ:CTCX$2.44 +0.02 (+0.83%) As of 07/3/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.GBS NYSE:GBS$1.78 -0.05 (-2.73%) As of 07/3/2025GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.InspireMD NYSE:NSPR$2.22 -0.02 (-0.89%) Closing price 04:00 PM EasternExtended Trading$2.16 -0.06 (-2.48%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Titan Medical NASDAQ:TMDIF$0.28 0.00 (-1.69%) As of 07/3/2025Titan Medical Inc. operates as a medical technology company. It focuses on the development and licensing of robotic assisted surgical technologies. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
